Company Presentation Scheduled for Friday, Sep 9, 2016 during 2:30 PM ET
;
Presentation can be noticed around webcast
NEW YORK, Sept. 09, 2016 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or a “Company”), a biopharmaceutical association building innovative targeted cargo immunotherapeutics for a diagnosis of modernized cancers, announced currently that Actinium will be presenting during a BioCentury 23rd Annual NewsMakers in a Biotech Industry Conference. The discussion is being hold on Sep 9, 2016 during a Millennium Broadway Hotel Conference Center in New York, NY.
Presentation Time: 2:30 PM ET
Presentation Room: Room 302/303
Breakout: 3:00 – 3:30 PM ET
Breakout Room: 301
The Company’s display will be webcasted and can be accessed by a following couple http://wsw.com/webcast/biocentury3/atnm. The display will be archived and accessible for playback around Actinium’s financier family page of a website http://ir.actiniumpharma.com/ir-calendar.
Actinium’s executive government will be accessible for 1-on-1 meetings with discussion attendees. To report a assembly with government hit Steve O’Loughlin, Vice President, Finance and Corporate Development during soloughlin@actiniumpharma.com or implement a conference’s assembly system: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
https://www.meetmax.com/sched/event_38669/investor_login.html?event_id=38669
About BioCentury NewsMakers Conference
NewsMakers ;presents a hand-picked organisation of open biotech companies whose corporate and regulatory milestones will expostulate batch prices. NewsMakers ;is famous as a industry’s pivotal venue for companies to take their story to Wall Street any Fall. Thus, ;NewsMakers ;remains a best event for business growth executives and pivotal members of a institutional investment and researcher communities to review records and consider a attention landscape.
Last year, some-more than 500 representatives congregated during ;NewsMakers, including income managers who tranquil some-more than $480 billion in equity assets, with over $50 billion dedicated to medical and $15 billion dedicated to biotech.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical association building innovative targeted cargo immunotherapeutics for a diagnosis of modernized cancers. Actinium’s targeted radioimmunotherapy products are formed on a exclusive smoothness height for a healing function of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in and with monoclonal antibodies. The Company’s lead radiopharmaceutical product claimant Iomab-B is designed to be used, on approval, in scheming patients for hematopoietic branch dungeon transplant, ordinarily referred to as bone pith transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical investigate of Iomab-B in adverse or relapsed AML patients over a age of 55 with a primary endpoint of durable finish remission. The Company’s second product candidate, Actimab-A, is stability a clinical growth in a Phase 1/2 hearing for patients newly diagnosed with AML over a age of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc. ;
This news recover contains “forward-looking statements” as tangible in a Private Securities Litigation Reform Act of 1995. These statements are formed on management’s stream expectations and engage risks and uncertainties, that might means tangible formula to differ materially from those set onward in a statements. The forward-looking statements might embody statements per product development, product potential, or financial performance. No forward-looking matter can be guaranteed and tangible formula might differ materially from those projected. Actinium Pharmaceuticals undertakes no requirement to publicly refurbish any forward-looking statement, either as a outcome of new information, destiny events, or otherwise.
Read More:
Actinium Pharmaceuticals Presenting during a BioCentury 23rd Annual NewsMakers in a Biotech Industry Conference
Article source
Related Posts:
Clearfield to Present during a 5th Annual Liolios Gateway…
Cesca Therapeutics Announces Conversion of $12.5 Million in…
Prothena Reports Second Quarter 2016 Financial Results;…
NOVADAQ Announces Appointment of Karen A. Licitra to the…
Cortera® Celebrates a 100th Cortera Pulse® Product Release